logo-loader
viewRUA Life Sciences

AorTech International: Accelerating development of its novel heart valve and graft products

AorTech International plc's (LON:AOR) Bill Brown introduces the company to Proactive London's Andrew Scott.

He says the business is based on a platform technology material called Elast-Eon which he says has been in human use for close to 15 years.

They licence out the tech as well as develop their own products using it.

He says they've now begun the manufacture of heart valves and early prototype valves are currently available for evaluation plus they're also nearing animal trials for its graft development programme.

Quick facts: RUA Life Sciences

Price: 102.9 GBX

AIM:RUA
Market: AIM
Market Cap: £16.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HANetf's Bitcoin ETC rapidly becomes most traded product on XETRA

ETC Group's Bradley Duke speaks with Proactive London’s Katie Pilbeam about the launch of its BTCetc Bitcoin Exchange Traded Crypto (BTCE) which was brought to market thanks to partner HANetf and has reached $50 million in AUM in less than two months from its launch. In July the BTCE was...

1 hour, 43 minutes ago

2 min read